<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5800">
  <stage>Registered</stage>
  <submitdate>30/10/2015</submitdate>
  <approvaldate>30/10/2015</approvaldate>
  <nctid>NCT02594124</nctid>
  <trial_identification>
    <studytitle>A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.</studytitle>
    <scientifictitle>An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443</scientifictitle>
    <utrn />
    <trialacronym>SHINE</trialacronym>
    <secondaryid>2015-001870-16</secondaryid>
    <secondaryid>ISIS 396443-CS11</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Spinal Muscular Atrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - nusinersen

Experimental: Group 1 - Participants transitioned from ISIS 396443-CS3B (NCT02193074)

Experimental: Group 2 - Participants transitioned from ISIS 396443-CS4 (NCT02292537)

Experimental: Group 3 - Participants transitioned from ISIS 396443-CS12 (NCT02052791)

Experimental: Group 4 - Participants transitioned from ISIS 396443-CS3A (NCT01839656)


Treatment: drugs: nusinersen
Administered by intrathecal (IT) injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants experiencing Adverse events (AEs) and/or Serious Adverse Events (SAEs)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant vital sign abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant weight abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant neurological examination abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant laboratory assessment abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant coagulation parameter abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from Baseline in concomitant medications</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who attained motor milestones as assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to death or respiratory intervention</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants not requiring permanent ventilation</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale - CHOP-INTEND tests includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0-4.</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Hammersmith Functional Motor Scale - The HFMSE tests motor function of patients with SMA. The original 20 item Hammersmith Functional Motor Scale was expanded to include 13 additional adapted items from the Gross Motor Function Measure to improve sensitivity for the higher functioning ambulant population.</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Revised Upper Limb Module (RULM)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in 6-Minute Walk Test (6MWT) - 6MWT: walking up and down a 25 metre track without aids or orthotics as fast as possible for 6 minutes. Lap splits, minute splits and total distance are recorded, in addition to any rests and falls.</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Compound Muscular Action Potential (CMAP) - CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles.</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in body length and/or height (for all participants)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in head circumference (for participants up to 36 months of age)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in chest circumference (for participants up to 36 months of age)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in arm circumference (for participants up to 36 months of age)</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of CMAP responders</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with motor milestones achieved</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants who achieved standing alone</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants who achieved walking with assistance</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with serious respiratory events</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants hospitalized</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of hospitalizations</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Cobb-Angle on X-Ray of the thoracolumbar spine</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Quality of Life (QOL) Questionnaires</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Disease-related hospitalizations and AEs</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival rate</outcome>
      <timepoint>Up to Day 1807</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Signed informed consent of parent or guardian and signed informed assent of
             participant, if indicated per participant's age and institutional guidelines.

          -  Completion of the index study in accordance with the study protocol or as a result of
             Sponsor decision (e.g., early termination of the index study) within the preceding 16
             weeks

        Key</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have any condition or worsening condition which in the opinion of the Investigator
             would make the participant unsuitable for enrollment, or could interfere with the
             participant participating in or completing the study

          -  Clinically significant abnormalities in hematology or clinical chemistry parameters or
             electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit
             that would render the participant unsuitable for participation in the study

          -  Participant's parent or legal guardian is not willing or able to meet standard of care
             guidelines (including vaccinations and respiratory syncytial virus prophylaxis if
             available), nor provide nutritional and respiratory support throughout the study

          -  Treatment with another investigational agent, biological agent, or device within one
             month of Screening, or 5 half-lives of study agent, whichever is longer

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>4/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>289</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Sydney Children's Hospital - Sydney</hospital>
    <hospital>Royal Children's Hospital, Children's Neuroscience Centre - Parkville</hospital>
    <postcode>2031 - Sydney</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong SAR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective is to evaluate the long-term safety and tolerability of nusinersen
      (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular
      Atrophy (SMA) who previously participated in investigational studies of nusinersen. The
      secondary objective is to examine the long-term efficacy of nusinersen administered by IT
      injection to participants with SMA who previously participated in investigational studies of
      nusinersen.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02594124</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>